Combining mTOR Inhibitors with Chemotherapy and Other Targeted Therapies in Advanced Breast Cancer: Rationale, Clinical Experience, and Future Directions

Por Yardley, Denise A.
Publicado em 2013

Drug Resistance and the Role of Combination Chemotherapy in Improving Patient Outcomes

Por Yardley, Denise A.
Publicado em 2013

Taxanes in the elderly patient with metastatic breast cancer

Por Yardley, Denise A
Publicado no Breast Cancer (Dove Med Press) (2015)

Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer

Por Yardley, Denise A
Publicado no Breast Cancer (Dove Med Press) (2016)

Healthcare Resource Use and Expenditures among Metastatic Breast Cancer Patients Treated with HER2-Targeted Agents

Por Meyer, Nicole, Hao, Yanni, Song, Xue, Shi, Nianwen, Johnson, William, Willemann Rogerio, Jaqueline, Yardley, Denise A.
Publicado em 2014

Molecular Profiling in Unknown Primary Cancer: Accuracy of Tissue of Origin Prediction

Por Greco, F. Anthony, Spigel, David R., Yardley, Denise A., Erlander, Mark G., Ma, Xiao-Jun, Hainsworth, John D.
Publicado em 2010

Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer

Por Yardley, Denise A., Kaufman, Peter A., Brufsky, Adam, Yood, Marianne Ulcickas, Rugo, Hope, Mayer, Musa, Quah, Cheng, Yoo, Bongin, Tripathy, Debu
Publicado em 2014

Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer

Por Rugo, Hope S., Brufsky, Adam M., Yood, Marianne Ulcickas, Tripathy, Debu, Kaufman, Peter A., Mayer, Musa, Yoo, Bongin, Abidoye, Oyewale O., Yardley, Denise A.
Publicado em 2013

Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study

Por Kaufman, Peter A., Brufsky, Adam M., Mayer, Musa, Rugo, Hope S., Tripathy, Debu, Yood, Marianne Ulcickas, Feng, Shibao, Wang, Lisa I., Quah, Cheng S., Yardley, Denise A.
Publicado em 2012

Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherap...

Por Yardley, Denise A., Hart, Lowell, Bosserman, Linda, Salleh, Mansoor N., Waterhouse, David M., Hagan, Maura K., Richards, Paul, DeSilvio, Michelle L., Mahoney, Janine M., Nagarwala, Yasir
Publicado em 2012

HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve,...

Por Miller, Kathy, Cortes, Javier, Hurvitz, Sara A., Krop, Ian E., Tripathy, Debu, Verma, Sunil, Riahi, Kaveh, Reynolds, Joseph G., Wickham, Thomas J., Molnar, Istvan, Yardley, Denise A.
Publicado no BMC Cancer (2016)

Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-...

Por Yardley, Denise A., Ismail-Khan, Roohi R., Melichar, Bohuslav, Lichinitser, Mikhail, Munster, Pamela N., Klein, Pamela M., Cruickshank, Scott, Miller, Kathy D., Lee, Min J., Trepel, Jane B
Publicado no J Clin Oncol (2013)

Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer...

Por Yardley, Denise A., Brufsky, Adam, Coleman, Robert E., Conte, Pierfranco F., Cortes, Javier, Glück, Stefan, Nabholtz, Jean-Mark A., O’Shaughnessy, Joyce, Beck, Robert M., Ko, Amy, Renschler, Markus F., Barton, Debora, Harbeck, Nadia
Publicado no Trials (2015)

Erratum to: ‘Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative b...

Por Yardley, Denise A., Brufsky, Adam, Coleman, Robert E., Conte, Pierfranco F., Cortes, Javier, Glück, Stefan, Nabholtz, Jean-Mark A., O’Shaughnessy, Joyce, Beck, Robert M., Ko, Amy, Renschler, Markus F., Barton, Debora, Harbeck, Nadia
Publicado no Trials (2016)

Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer

Por Kaufman, Peter A, Bloom, Kenneth J, Burris, Howard, Gralow, Julie R, Mayer, Musa, Pegram, Mark, Rugo, Hope S, Swain, Sandra M, Yardley, Denise A, Chau, Miu, Lalla, Deepa, Yoo, Bongin, Brammer, Melissa G, Vogel, Charles L
Publicado no Cancer (2014)

Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer

Por Vahdat, Linda T., Layman, Rachel, Yardley, Denise A., Gradishar, William, Salkeni, Mohamad A., Joy, Anil Abraham, Garcia, Agustin A., Ward, Patrick, Khatcheressian, James, Sparano, Joseph, Rodriguez, Gladys, Tang, Shande, Gao, Ling, Dalal, Rita P., Kauh, John, Miller, Kathy
Publicado no Oncologist (2017)

Everolimus Plus Exemestane in Postmenopausal Patients with HR(+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

Por Yardley, Denise A., Noguchi, Shinzaburo, Pritchard, Kathleen I., Burris, Howard A., Baselga, José, Gnant, Michael, Hortobagyi, Gabriel N., Campone, Mario, Pistilli, Barbara, Piccart, Martine, Melichar, Bohuslav, Petrakova, Katarina, Arena, Francis P., Erdkamp, Frans, Harb, Wael A., Feng, Wentao, Cahana, Ayelet, Taran, Tetiana, Lebwohl, David, Rugo, Hope S.
Publicado em 2013

Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR(+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

Por Yardley, Denise A., Noguchi, Shinzaburo, Pritchard, Kathleen I., Burris, Howard A., Baselga, José, Gnant, Michael, Hortobagyi, Gabriel N., Campone, Mario, Pistilli, Barbara, Piccart, Martine, Melichar, Bohuslav, Petrakova, Katarina, Arena, Francis P., Erdkamp, Frans, Harb, Wael A., Feng, Wentao, Cahana, Ayelet, Taran, Tetiana, Lebwohl, David, Rugo, Hope S.
Publicado no Adv Ther (2014)

Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer

Por Tolaney, Sara M., Barry, William T., Dang, Chau T., Yardley, Denise A., Moy, Beverly, Marcom, P. Kelly, Albain, Kathy S., Rugo, Hope S., Ellis, Matthew, Shapira, Iuliana, Wolff, Antonio C., Carey, Lisa A., Overmoyer, Beth A., Partridge, Ann H., Guo, Hao, Hudis, Clifford A., Krop, Ian E., Burstein, Harold J., Winer, Eric P.
Publicado no N Engl J Med (2015)

Quantitative measurement of HER2 expression in breast cancers: comparison with ‘real-world’ routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with...

Por Yardley, Denise A, Kaufman, Peter A, Huang, Weidong, Krekow, Lea, Savin, Michael, Lawler, William E, Zrada, Stephen, Starr, Alexander, Einhorn, Harvey, Schwartzberg, Lee S, Adams, John W, Lie, Yolanda, Paquet, Agnes C, Sperinde, Jeff, Haddad, Mojgan, Anderson, Steve, Brigino, Marlon, Pesano, Rick, Bates, Michael P, Weidler, Jodi, Bosserman, Linda
Publicado no Breast Cancer Res (2015)